Navigation Links
CVBT Closes Clinical Development Agreement for Coronary Heart Disease Drug Candidate
Date:11/13/2008

LAS VEGAS, Nov. 13 /PRNewswire-FirstCall/ -- CardioVascular BioTherapeutics, Inc. (OTC Bulletin Board: CVBT) (the "Company") has entered into its first clinical development agreement for its Coronary Heart Disease drug candidate with Cardio Neo-Genesis, LP ("CNG"). The agreement, dated November 11, 2008 states that CNG can fund up to $15,000,000 of the clinical development for the Company's Coronary Heart Disease (CHD) drug candidate. The agreement also provides for a royalty to CNG payable from 5% of CVBT's cash-flow stream on its CHD drug up to 20 times return to CNG's limited partners.

"CVBT is currently utilizing clinical development agreements to fund and advance our drug development candidates," according to Mr. Mickael A. Flaa, CVBT's Chief Financial Officer. Mr. Flaa continued, "Given the stress in the financial markets at this time, we looked to the lessons of history for a strategy to finance CVBT's drug development program. The clinical development arrangements that CVBT has entered into are similar in structure to those used successfully by Amgen, Genentech, Biogen, and others over 20 years ago to fund their drug development programs."

"This development agreement is a positive step in advancing CVBT's CHD drug candidate given today's financial markets," said Mr. Daniel C. Montano, CVBT's CEO. Mr. Montano continued, "I believe that CVBT's existing shareholders will benefit from this new source of funding which does not permanently dilute their shareholdings."

About CardioVascular BioTherapeutics

CVBT (OTCBB: CVBT) is a biopharmaceutical company developing human FGF-1 for cardiovascular diseases characterized by inadequate blood flow to a tissue or organ. In addition to the Phase II trial it is conducting in patients with severe coronary heart disease, the company has two FDA-authorized clinical trials in the areas of impaired wound healing seen in diabetics and in patients suffering from peripheral artery disease of the legs. An additional study is being conducted in patients with chronic back pain who may have perfusion defects to their spine. For more information about CardioVascular BioTherapeutics, Inc. please visit http://www.cvbt.com.

CardioVascular BioTherapeutics, Inc.

Allison Caplan, (702) 839-7200

acaplan@cvbt.com


'/>"/>
SOURCE CardioVascular BioTherapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
2. Genmab Discloses Target and Development Plans for HuMax-Inflam
3. Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals
4. RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited
5. Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund
6. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
7. BioVex Closes Second Round of Series E Financing
8. Pharmaxis Closes Share Purchase Plan
9. The closest look ever at native human tissue
10. Helix BioPharma closes $16.9 million private placement of common shares
11. Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... April 27, 2016 , ... ... to announce the appointment of John Tilton as Chief Commercial Officer.  Mr. Tilton ... one of the founding commercial leaders responsible for the commercialization of multiple orphan ...
(Date:4/27/2016)... ... April 27, 2016 , ... Global Stem Cells Group and ... Symposium as other research and development initiatives for potential stem cell protocol management for ... Stem Cells Group executives began meeting to establish a working agenda and foster initiatives ...
(Date:4/26/2016)... ... April 26, 2016 , ... The European Patent Office ... as one of three finalists for the European Inventor Award 2016 in the category ... will be announced at a ceremony in Lisbon on June 9th. , The human ...
(Date:4/26/2016)... ... 26, 2016 , ... Seattle based non-profit, The Institute for ... Corporation. The grant will be used to further the scientific research goals of ... http://www.ivsci.org , In accounting the grant to the IVS, Mr. Glenn ...
Breaking Biology Technology:
(Date:3/29/2016)... March 29, 2016 LegacyXChange, Inc. ... "LEGX" and SelectaDNA/CSI Protect are pleased to announce our ... in a variety of writing instruments, ensuring athletes signatures ... created collectibles from athletes on LegacyXChange will be assured ... the DNA. Bill Bollander , CEO ...
(Date:3/18/2016)... --> --> Competitive Landscape Analysis ... Physical infrastructure and Perimeter Surveillance & Detection Systems ... and the continuing migration crisis in the Middle ... led visiongain to publish this unique report, which is crucial ... & security companies in the border security market and the ...
(Date:3/14/2016)... 14, 2016 http://www.apimages.com ) ... --> - Renvoi : image disponible via AP ... --> --> DERMALOG, le leader ... nouveaux lecteurs d,empreintes digitales pour l,enregistrement des réfugiés ... utilisé pour produire des cartes d,identité aux réfugiés. ...
Breaking Biology News(10 mins):